
Toleranzia Investor Relations Material
Latest events

Q1 2025
6 May, 2025

Q4 2024
21 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Toleranzia
Access all reports
Toleranzia AB is a biotechnology company specializing in the development of protein-based drugs for the treatment of autoimmune diseases. The company leverages its proprietary platform to create therapeutic proteins aimed at inducing immune tolerance in patients, addressing the underlying causes of autoimmune conditions rather than merely alleviating symptoms. Toleranzia focuses on diseases with significant unmet medical needs, striving to provide innovative treatments that can improve patients' quality of life. The company is headquartered in Gothenburg, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
TOL
Country
🇸🇪 Sweden